Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 71.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,562 shares of the biopharmaceutical company’s stock after selling 6,327 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Regeneron Pharmaceuticals were worth $1,439,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $226,000. Ameritas Advisory Services LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $45,000. IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals by 20.1% during the 2nd quarter. IFP Advisors Inc now owns 1,230 shares of the biopharmaceutical company’s stock valued at $646,000 after acquiring an additional 206 shares in the last quarter. Finally, Concurrent Investment Advisors LLC boosted its position in Regeneron Pharmaceuticals by 136.4% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,622 shares of the biopharmaceutical company’s stock worth $852,000 after acquiring an additional 936 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Scotiabank upped their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday. HSBC upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $793.81.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $754.91 on Wednesday. The company has a 50-day moving average of $758.15 and a 200-day moving average of $661.69. The firm has a market cap of $79.34 billion, a price-to-earnings ratio of 18.16, a price-to-earnings-growth ratio of 2.10 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $12.07 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.